Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a conditionally binding ROR2-targeting ADC, in Patients with Treatment Refractory HPV+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

ozuriftamab vedotin (BA3021) - BioAtla

https://astro.confex.com/astro/hncs2026/meetingapp.cgi/Paper/73079

Douglas Adkins; Kartik Aysola; Jeremy Cetnar; Kyechin Chen; Jaspreet Grewal; Alan Ho; Kathleen Kerrigan; Judith Llorin-Sangalang; Jochen Lorch; Jamal Misleh; Jeffery Russell; Jacob Thomas; Winston Wong

Mar 1, 2026